title: Evolving approaches with interferon alfa in chronic myelogenous leukemia.
authors.affiliation: Institute of Hematology, University of Pavia, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Morra
authors.forename: G
authors.initials: G
authors.lastname: Alimena
authors.forename: M
authors.initials: M
authors.lastname: Lazzarino
authors.forename: A M
authors.initials: AM
authors.lastname: Liberati
authors.forename: E
authors.initials: E
authors.lastname: Montefusco
authors.forename: P
authors.initials: P
authors.lastname: Bernasconi
authors.forename: M
authors.initials: M
authors.lastname: Mancini
authors.forename: E
authors.initials: E
authors.lastname: Donti
authors.forename: S
authors.initials: S
authors.lastname: Merante
authors.forename: P
authors.initials: P
authors.lastname: Caricchi
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003561:Cytarabine; D006918:Hydroxyurea